Table 2.
Sponsor | Vaccine | Phase trial | Reported cutaneous adverse reactions (non-injection site related) in vaccine groups |
---|---|---|---|
AstraZenica | ChAdOx1 nCoV-19 | I,II,III | Rosacea flare, Pruritus; cellulitis |
Moderna | mRNA-1273 | I/II/III |
-1 instance of transient urticaria on both legs 5 days after receiving first dose of vaccine 25mcg vaccine; -1 instance of a maculopapular rash -2 instances of hypersensitivity reaction to previously injected facial dermal filler (deemed serious adverse events) -1 instance of angioedema of lips in subject with history of lip dermal filler injection |
Pfizer-BioNTech | BNT162b2 | I,II,III | Hypersensitivity-related adverse events 137 participants, 0.63% |